随着A股市场AI应用概念的持续火爆，港股市场AI医疗股亦跟随集体爆发。其中，中国领先的线上慢病 管理平台方舟健客(6086.HK)今日盘中一度放量飙升超43%至3.4港元，为连续第二日大涨，股价创2个月 新高。 消息面上，近期，方舟健客与腾讯健康举行"AI+慢病管理"解决方案发布会，标志着国内慢病管理领域 迈入全新发展阶段。双方强强联合，将为"AI+慢病管理"领域数智化升级提供强有力的技术支撑。 另外值得注意的是，格隆汇研究院昨日发布研报《重塑认知：方舟健客的深度价值重估之路 ——"AI+"生态蓝图正在加速展开，领跑下一个十年》指出，"优质医生资源&丰富产品矩阵"是公司的 核心特点，作为以长期医患关系为基础的生态系统使方舟健客能够更好地把握慢性病患者巨大的客户终 身价值，同时也满足医疗保健系统中其他关键利益相关者(包括医生和制药公司)的需求。1H25业绩增长 是公司慢病患者用户价值释放的拐点，随着公司"AI+H2H创新生态"的持续构建，客户价值有望进一步 凸显。 ...

Core Viewpoint - Ark Health (06086) has seen a significant stock price increase, rising nearly 40% during trading, with a current price of 2.98 HKD and a trading volume of 136 million HKD, following the announcement of a partnership with Tencent Health to launch an "AI + Chronic Disease Management" solution [1] Group 1: Partnership and Collaboration - The collaboration between Ark Health and Tencent Health marks a new development stage in the domestic chronic disease management sector [1] - The partnership aims to provide comprehensive support for industry partners, from technology validation to scenario implementation and large-scale deployment, enhancing the intelligent, compliant, and efficient development of the industry [1] Group 2: Technological Strengths - Ark Health is recognized as a leading "AI + Chronic Disease Management" service platform, leveraging its innovative "AI + H2H (Hospital to Home) smart healthcare ecosystem" to establish unique technological advantages and practical experience in chronic disease management [1] - Tencent Cloud, as a leading cloud service provider, excels in key technology areas such as cloud computing, big data, and artificial intelligence, complementing Ark Health's strengths [1] Group 3: Market Impact - The strong collaboration between Ark Health and Tencent Health is expected to provide robust technical support for the digital transformation and upgrade of the "AI + Chronic Disease Management" sector [1]

Group 1 - Ark Health (06086) experienced a significant stock increase of nearly 40%, currently trading at 3.21 HKD with a transaction volume of 1.03 million HKD [1] - The recent collaboration between Ark Health and Tencent Health marks a new development phase in chronic disease management in China, providing comprehensive support from technology validation to large-scale deployment [1] - Ark Health, as a leading "AI + chronic disease management" service platform, leverages its innovative "AI + H2H (Hospital to Home) smart healthcare ecosystem" to establish a unique technological advantage in chronic disease management [1] Group 2 - The partnership represents a systematic output of technological capabilities and is a significant exploration of the deep integration model of "artificial intelligence + healthcare" [2] - In response to recent policy initiatives from the National Health Commission and other departments promoting the application of AI in healthcare, this collaboration aims to drive the healthy development of the AI healthcare industry [2]

Core Viewpoint - Ark Health (06086) has seen a significant stock increase of nearly 40%, currently trading at 3.21 HKD, following the announcement of a collaboration with Tencent Health on an "AI + Chronic Disease Management" solution, marking a new development phase in the domestic chronic disease management sector [1] Group 1: Company Collaboration - The partnership between Ark Health and Tencent Health aims to provide comprehensive support for industry partners, from technology validation to scenario implementation and large-scale deployment, injecting new momentum into the intelligent, compliant, and efficient development of the industry [1] - Ark Health, as a leading "AI + Chronic Disease Management" service platform in China, leverages its innovative "AI + H2H (Hospital to Home) smart medical ecosystem" to establish unique technological advantages and practical experience in chronic disease management [1] - Tencent Cloud, recognized as a leading cloud service provider, excels in key technology areas such as cloud computing, big data, and artificial intelligence, enhancing the partnership's capability to support the digital upgrade of the "AI + Chronic Disease Management" field [1] Group 2: Industry Context - This collaboration represents not only a systematic output of technical capabilities but also an important exploration of the deep integration model of "Artificial Intelligence + Healthcare" [2] - In response to recent policy initiatives from the National Health Commission and other departments promoting the application of "Artificial Intelligence + Healthcare," the partnership aligns with national efforts to advance the healthy development of the AI healthcare industry [2]

Group 1 - The core viewpoint of the report is that Ark Health (6086.HK) is positioned as China's largest online chronic disease management platform, with a significant user base and high repurchase rates [1] - As of the first half of 2025, the company has over 11.9 million monthly active users and a repurchase rate of 85.4%, with registered doctors increasing to 229,000, 58.9% of whom are from top-tier hospitals [1] - The platform offers over 216,000 drug SKUs, with 62% being prescription drugs, ensuring a robust supply of quality medical resources for chronic disease patients [1] Group 2 - The chronic disease management market in China is projected to grow from RMB 45.5 billion in 2023 to RMB 600 billion by 2030, with a compound annual growth rate (CAGR) of 44.5% [2] - The demand in specialized fields such as weight loss and metabolism is particularly strong, driven by the proliferation of innovative drugs, which are key growth engines for the industry [2] - The company leverages its "AI+H2H" model to capitalize on this market opportunity, with projected revenues of HKD 3.5 billion in 2025 and HKD 4.8 billion in 2026, corresponding to price-to-sales ratios of 0.8x and 0.6x, respectively, compared to industry averages of 4.9x and 4.1x [2]

Group 1: Company Overview - Ark Health (6086.HK) is China's leading online chronic disease management platform, established in 2015, characterized by "high-quality doctor resources and a rich product matrix" [1] - As of H1 2025, the company has over 11.9 million monthly active users with a repurchase rate of 85.4% [1] - The platform has registered 229,000 doctors, with 58.9% from top-tier hospitals, providing online medical consultation, electronic prescriptions, and prescription reallocation services [1] Group 2: Market Potential - The online consumer-facing chronic disease management market in China is projected to grow from RMB 45.5 billion in 2023 to RMB 600 billion by 2030, with a compound annual growth rate (CAGR) of 44.5% [2] - The market penetration rate is expected to rise from 2.9% to 16.1%, driven by strong demand in specialized fields such as weight loss and metabolism, alongside the proliferation of innovative drugs [2] Group 3: Strategic Positioning - The company leverages an "AI + H2H" model to capitalize on high-growth opportunities in the chronic disease management sector, highlighting its strategic value [2] - The "familiar doctor-patient" relationship fosters trust and supports long-term management, enhancing both doctor efficiency and patient management value, contributing to the high repurchase rate [2] Group 4: Financial Outlook - The company's stock price is currently HKD 2.10 per share, with a market capitalization of approximately HKD 3.28 billion [3] - Revenue is expected to reach HKD 3.5 billion in 2025 and HKD 4.8 billion in 2026, corresponding to price-to-sales (P/S) ratios of 0.8x and 0.6x, respectively, compared to industry averages of 4.9x and 4.1x [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 FF301 II. 已發行股份及/或庫存股份變動 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06086 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 USD | | 50,000 | 本月底法定/註冊股本總 ...

Core Insights - The article highlights the innovative integration of AI in chronic disease management by Fangzhou Jianke, showcasing its potential to address global health challenges [1][2][3] Group 1: Company Overview - Fangzhou Jianke has been a pioneer in the "Internet + Chronic Disease Management" sector since 2015, developing a Hospital to Home (H2H) smart healthcare ecosystem [2] - The company has upgraded its platform to create a more professional, intelligent, and efficient "AI + H2H Smart Healthcare Ecosystem," enhancing patient care from hospital to home [2] Group 2: AI Technology Integration - AI technology is fully integrated into Fangzhou Jianke's healthcare services, utilizing the self-developed Xing Shi model, which includes multi-modal capabilities such as image and voice recognition, and natural language processing [2] - The AI health steward provides continuous real-time interaction, assisting patients in managing their health effectively, while the AI academic assistant addresses urgent clinical decision-making needs and improves the efficiency of medical information retrieval for doctors [2][3] Group 3: Industry Impact - The integration of AI not only enhances the operational efficiency of the H2H smart healthcare ecosystem but also builds trust among patients and doctors by addressing their pain points [3] - Fangzhou Jianke aims to set a new benchmark in the "AI + Internet Healthcare" sector, promoting standardized and intelligent development in chronic disease management, and providing a replicable "Chinese solution" for global health challenges [3]

Core Insights - Tencent Holdings (00700), Alibaba-W (09988), and Hong Kong Exchanges (00388) led the market in net inflows, with amounts of 1.115 billion, 1.055 billion, and 309 million respectively [1] - China Mobile (00941), Luoyang Molybdenum (03993), and CICC (03908) experienced the highest net outflows, with amounts of -1.053 billion, -184 million, and -181 million respectively [1] - In terms of net inflow ratios, China Telecom Services (00552), Yihua Tong (02402), and Sunshine Insurance (06963) topped the list with ratios of 167.31%, 126.18%, and 118.17% respectively [1] Net Inflow Rankings - Tencent Holdings (00700) had a net inflow of 1.115 billion, representing a 13.09% increase, closing at 614.500 [2] - Alibaba-W (09988) saw a net inflow of 1.055 billion, with a 12.23% increase, closing at 146.400 [2] - Hong Kong Exchanges (00388) recorded a net inflow of 309 million, with a 24.77% increase, closing at 407.000 [2] Net Outflow Rankings - China Mobile (00941) faced a net outflow of -1.053 billion, a decrease of -54.21%, closing at 83.700 [2] - Luoyang Molybdenum (03993) had a net outflow of -184 million, down by -29.82%, closing at 19.100 [2] - CICC (03908) experienced a net outflow of -181 million, a decrease of -30.22%, closing at 20.540 [2] Net Inflow Ratio Rankings - China Telecom Services (00552) achieved a net inflow ratio of 167.31%, with a net inflow of 26.5926 million, closing at 4.520 [3] - Yihua Tong (02402) had a net inflow ratio of 126.18%, with a net inflow of 26.5481 million, closing at 23.980 [3] - Sunshine Insurance (06963) recorded a net inflow ratio of 118.17%, with a net inflow of 31.5558 million, closing at 3.940 [3]

Group 1 - The core viewpoint of the news is that Ark Health has been recognized as the "Annual Outstanding Digital Intelligence Enterprise" for its continuous innovation in the "AI+H2H (Hospital to Home) smart healthcare ecosystem" [1] - Ark Health has won this award for two consecutive years, indicating its sustained innovation and recognition in the digital healthcare sector [1] - The "Yee Guan Star" list aims to discover and commend enterprises and products that have achieved outstanding results in digital transformation, promoting deep communication and cooperation across industries [1] Group 2 - According to a recent report by Yi Guan Analysis, AI precision medicine is evolving from a "treatment-driven" approach to a "whole life health cycle" model, with Ark Health leading the implementation of the "AI+H2H" model in chronic disease management [2] - The report highlights that the AI precision medicine market in China is expected to reach 35.1 billion yuan in 2024 and is projected to grow to 76 billion yuan by 2028 [2] - Ark Health has developed its own AI model that integrates multi-modal recognition, natural language processing, and knowledge reasoning capabilities, significantly enhancing service efficiency and user experience in chronic disease management [2] - The company aims to empower chronic disease management services through technology and collaborate with a broader range of industry partners to promote equitable allocation of quality medical resources and personalized health services [2]